Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

Per Olav Vandvik,Hao Qin ,Yeoungjee Cho,Alejandro Díaz González-Colmenero,Reem A. Mustafa ,Rita McMorrow,Antonio Nicolucci,Britta Tendal,Fernando Díaz González-Colmenero,Andrea Flores Rodríguez,Sophanny Tiv,Patrizia Natale,Suetonia C. Palmer ,Marcello Tonelli,Xu Zhou,Melissa L. Burke ,Jiali Liu,Marinella Ruospo,Heath White,Nithin Kolanu,Yuanchen Liu,René Rodríguez-Gutiérrez ,Lucia Gagliardi,Valeria Saglimbene,Michael Walsh,Labib Imran Faruque ,Annie‐Claire Nadeau‐Fredette ,David J. Tunnicliffe ,Ana Karina Raygoza Cortez,Tanya Millard,Sunil V. Badve ,David W. Johnson ,Nasreen Ahmad,Anita Lloyd,Yang Wang,Maria Chiara Rossi,Giovanni F.m. Strippoli ,Xiangyang Chen,Sheyu Li,Rahul Barmanray ,Gordon Guyatt,Surya Sutanto,Ricardo Cesar Solis,Ling Li

doi:10.1136/bmj.m4573

Abstract

ObjectiveTo evaluate sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes at varying cardiovascular and renal risk.DesignNetwork meta-analysis.Data sourcesMedline, Embase, and Cochrane CENTRAL...

Full Text